Study finds immunotherapy Pembrolizumab with chemotherapy improves early-stage breast cancer outcomes in trial involving 1,278 patients.

Study suggests immunotherapy, Pembrolizumab (Keytruda), combined with chemotherapy before and after surgery may improve outcomes for early-stage breast cancer patients, regardless of age or menopausal status. The Keynote-756 trial involving 1,278 patients with invasive ductal carcinoma showed a 24.3% PCR rate among those treated with Pembrolizumab compared to 15.6% with a placebo. The drug is currently used for treating triple-negative breast cancer and could be submitted for licensing for other types of cancer.

March 19, 2024
9 Articles